StockTipsArenaBeta

BUY Aurobindo Pharma — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: Swing (≤2wk)21 Sept 2026via NDTV Profit (Live)

Entry₹1,709.8Inferred
Target₹2,000
Total upside +16.97% (call closed)
Stop loss₹1,599-6.48% risk
At expiry₹1,674.95 Oct 2026, 3:30 pm
Expired-2.04%auction close
Follow Sachin Janardan Sarvade for new calls(15% target hit, 91 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 204 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 5 Oct 2026
17 supporting2 neutral1 opposing
Supports the BUY call (17)

Aurobindo Pharma gets USFDA final approval for Perampanel tablets

NewsCnbc-Tv18·3 Oct · yesterday

(opens in new tab)

Aurobindo Pharma received final approval from the USFDA for Perampanel Tablets in multiple strengths.

BSE · Company Update·3 Oct · yesterday

(opens in new tab)

Aurobindo Pharma's subsidiary, A1 USA Inc, has acquired 100% ownership of A1 Biochem Labs LLC for USD 15.247 million to expand its contract research and development capabilities.

NSE · Acquisition·2 Oct · 2d ago

(opens in new tab)

Aurobindo Pharma launches Adquey in US; Nuvama sees $300 million peak sales

NewsCnbc-Tv18·1 Oct · 4d ago

(opens in new tab)

Aurobindo Pharma arm Acrotech Biopharma launches ADQUEY in US dermatology market

NewsCnbc-Tv18·30 Sept · 4d ago

(opens in new tab)
Neutral / worth noting (2)

These four pharma stocks will be reacting to important news updates today

NewsCnbc-Tv18·5 Oct · today

(opens in new tab)

Aurobindo Pharma Ltd has announced the acquisition of a step-down subsidiary located in the USA.

BSE · Company Update·2 Oct · 2d ago

(opens in new tab)
Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Every call and its outcome